Low ‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia

In conclusion, preliminary results indicated that low-dose venetoclax combined with azacitidine is effective and safe for the treatment of older and frail patients with newly diagnosed AML, providing a new treatment option for these patients.PMID:38586209 | PMC:PMC10996028 | DOI:10.3892/ol.2024.14362

Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Chunmeng Rong Fang Yang Yalu Chen Ming Wang Cheng Ai Yuqing Luo Panpan Gao Yiqin Weng Xiaguang Huang Meier Gu Weiping Huang Yongming Xia Source Type: research